Background and activities
Professor Kaisa Lehti's Research Group
Norwegian Cancer Society Project: Strategies for combinatorial tumour microenvironment targeting and ex vivo tissue-based drug testing to eradicate metastatic cancers.
Andrew's PhD research project focussed on epithelial cancers arising from loss of the cell-to-cell adhesion protein E-cadherin (CDH1). Dysfunctional CDH1 underpins cancers such as diffuse gastric cancer and lobular breast cancer. This PhD project involved testing novel drug combinations in vitro for potential therapeutic utility in these cancer subtypes.
Andrew then moved to Lund University, Sweden, to undertake a postdoctoral project researching novel molecular compounds for therapeutic use in respiratory diseases. This project involved extensive use of in vivo mouse models of acute lung injury and pulmonary fibrosis to evaluate the compounds' effects.
Andrew's background in drug testing using in vitro and in vivo models of cancer and fibrosis provides him with a vast array of experience to contribute towards Professor Lehti's research group.
Education and Degrees:
2012: BSc, Genetics, University of Otago, New Zealand
2013: BSc(Hons), First Class Honours, Genetics, University of Otago, New Zealand
2018: PhD, Biochemistry, University of Otago, New Zealand
2019-2021: Postdoctoral Research Fellow, Lund University, Sweden
2021-Present: Postdoctoral Research Fellow, NTNU, Norway